FK506 VERSUS CYCLOSPORINE AS PRIMARY IMMUNOSUPPRESSIVE AGENT FOR ORTHOTOPIC LIVER ALLOGRAFT RECIPIENTS - HISTOLOGIC AND IMMUNOPATHOLOGIC OBSERVATIONS

被引:25
|
作者
HYTIROGLOU, P
LEE, R
SHARMA, K
THEISE, ND
SCHWARTZ, M
MILLER, C
THUNG, SN
机构
[1] MT SINAI SCH MED,LILLIAN & HENRY M STRATTON HANS POPPER DEPT PATHO,NEW YORK,NY 10029
[2] MT SINAI SCH MED,DEPT SURG,NEW YORK,NY 10029
关键词
D O I
10.1097/00007890-199312000-00022
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We investigated possible explanations for the common occurrence of perivenular lesions in liver allografts of patients on FK506 within a few weeks to several months after OLT. Hematoxylin and eosin-stained sections of pre- and postperfusion biopsy specimens and day 7 posttransplant protocol biopsy specimens from 31 patients, randomly assigned to either FK5O6 or CsA as primary immunosuppressive agent, were reviewed, and immunohistochemical stains for HLA-DR antigen and S-100 protein were performed by the avidin-biotin peroxidase complex method. The histologic features of cellular rejection in the portal tracts of day 7 posttransplant allograft biopsy specimens from patients on FK506 were milder than those from patients on CsA. Immunohistochemical stains for HLA-DR showed intense positivity in a variety of cell types in day 7 post-transplant specimens from both groups, including sinusoidal-lining cells, bile duct epithelial cells, vascular endothelial cells, inflammatory cells, and occasional injured hepatocytes. Although diffuse lobular staining was seen in the majority of cases in both groups, either with or without rejection, liver biopsy specimens from patients on FK506 showed concentration of positively stained cells in perivenular regions more often, and at a lower overall histologic grade of rejection, than specimens from patients on CsA. There were no differences in the number and distribution of S-100 protein-positive dendritic APC between biopsy specimens from FK506 versus CsA-treated patients, or between specimens with and without cellular rejection in either group. It is suggested that the development of perivenular injury, which is seen frequently in allograft biopsy specimens from patients on FK506 obtained at various intervals after transplantation, may be related to drug toxicity rather than to the process of allograft rejection.
引用
收藏
页码:1389 / 1394
页数:6
相关论文
共 50 条
  • [21] DIABETOGENICITY OF FK506 VERSUS CYA IN LIVER-TRANSPLANT RECIPIENTS
    JINDAL, RM
    EMRE, S
    MENESES, P
    MOR, E
    KADIAN, M
    KISHIKAWA, K
    SCHWARTZ, M
    MILLER, CM
    HEPATOLOGY, 1993, 18 (03) : 745 - 745
  • [22] Renal allograft rejection in patients receiving FK506 as primary immunosuppressive therapy.
    Preston, R
    Ball, S
    Cairns, T
    Contis, J
    Hakim, N
    Palmer, A
    Papalois, V
    Taube, D
    KIDNEY INTERNATIONAL, 1999, 55 (06) : 2592 - 2592
  • [23] Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine
    Park, KM
    Hay, JE
    Lee, SG
    Lee, YJ
    Wiesner, RH
    Porayko, MK
    Krom, RAF
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (03) : 1738 - 1740
  • [24] SERUM-LIPID CHANGES IN LIVER-TRANSPLANT RECIPIENTS IN A PROSPECTIVE TRIAL OF CYCLOSPORINE VERSUS FK506
    JINDAL, RM
    POPESCU, I
    EMRE, S
    SCHWARTZ, ME
    BOCCAGNI, P
    MENESES, P
    MOR, E
    SHEINER, P
    MILLER, CM
    TRANSPLANTATION, 1994, 57 (09) : 1395 - 1398
  • [25] LONG-TERM EFFECTS OF FK506 FOLLOWING CONVERSION FROM CYCLOSPORINE TO FK506 FOR CHRONIC REJECTION IN LIVER-TRANSPLANT RECIPIENTS
    FUNG, JJ
    JAIN, A
    HAMMAD, I
    DOYLE, H
    SELBY, R
    TZAKIS, AG
    TODO, S
    STARZL, TE
    HEPATOLOGY, 1993, 18 (04) : A74 - A74
  • [26] RENAL SODIUM HANDLING WITH CYCLOSPORINE-A AND FK506 AFTER ORTHOTOPIC LIVER-TRANSPLANTATION
    CANZANELLO, VJ
    TEXTOR, SC
    TALER, SJ
    WILSON, DJ
    SCHWARTZ, L
    WIESNER, RH
    PORAYKO, MK
    KROM, RA
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 5 (11): : 1910 - 1917
  • [27] CONVERSION FROM CYCLOSPORINE TO FK-506 IN LIVER ALLOGRAFT RECIPIENTS WITH CYCLOSPORINE-RELATED COMPLICATIONS
    FUNG, JJ
    TODO, S
    JAIN, A
    MCCAULEY, J
    ALESSIANI, M
    SCOTTI, C
    STARZL, TE
    TRANSPLANTATION PROCEEDINGS, 1990, 22 (01) : 6 - 12
  • [28] Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients
    Maes, BD
    Lemahieu, W
    Kuypers, D
    Evenepoel, P
    Coosemans, W
    Pirenne, J
    Vanrenterghem, YFCH
    AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (10) : 989 - 992
  • [29] RANDOMIZED TRIAL COMPARING TACROLIMUS (FK506) AND CYCLOSPORINE IN PREVENTION OF LIVER ALLOGRAFT-REJECTION
    NEUHAUS, P
    PICHLMAYR, R
    WILLIAMS, R
    BECHSTEIN, WO
    BLUMHARDT, G
    MCMASTER, P
    MAYER, D
    BUCKELS, J
    CALNE, R
    FRIEND, P
    JOUGHIN, C
    WINKLER, M
    RINGE, B
    OTTO, G
    BLEYL, J
    DEVLIN, J
    OGRADY, J
    GROTH, C
    ERICZON, B
    DURAJ, F
    BISMUTH, H
    SAMUEL, D
    RUCAY, P
    LANCET, 1994, 344 (8920): : 423 - 428
  • [30] A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation - A report of the United States FK506 study group
    Wiesner, RH
    TRANSPLANTATION, 1998, 66 (04) : 493 - 499